On 2014 Nov 14, Christopher Southan commented:
While they followed Roche into BACE2-inhibition patents for diabetes, Novartis have since published a abstract contradicting the target status http://cdsouthan.blogspot.se/2014/12/bace2-as-diabetes-target-or-maybe-not.html
On 2014 Feb 22, Christopher Southan commented:
The 46 PubChem structures refered to in this article can be retrieved via http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/1zuPd27ihNyflkXH7XHUWAU5L/ The CIDs are specified in the text, with activity values aligned to the example numbers. Note SureChEMBL SIDs may connect to the patents where addtional SAR data can be found. An open version of the PMID:23506624 text can be found at http://figshare.com/articles/BACE2_as_a_new_diabetes_target_a_patent_review_2010_2012_/977844
On 2014 Feb 22, Christopher Southan commented:
The 46 PubChem structures refered to in this article can be retrieved via http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/1zuPd27ihNyflkXH7XHUWAU5L/ The CIDs are specified in the text, with activity values aligned to the example numbers. Note SureChEMBL SIDs may connect to the patents where addtional SAR data can be found. An open version of the PMID:23506624 text can be found at http://figshare.com/articles/BACE2_as_a_new_diabetes_target_a_patent_review_2010_2012_/977844
On 2014 Nov 14, Christopher Southan commented:
While they followed Roche into BACE2-inhibition patents for diabetes, Novartis have since published a abstract contradicting the target status http://cdsouthan.blogspot.se/2014/12/bace2-as-diabetes-target-or-maybe-not.html